| dc.contributor | Flores-Torales, E., Departamento de Biología Celular y Molecular, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Mexico, Sangre de Cordón S.A. de C.V., Guadalajara, Mexico; Orozco-Barocio, A., Departamento de Biología Celular y Molecular, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Mexico; Gonzalez-Ramella, O.R., Sangre de Cordón S.A. de C.V., Guadalajara, Mexico, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Mexico; Carrasco-Yalan, A., Sangre de Cordón S.A. de C.V., Guadalajara, Mexico; Gazarian, K., Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico; Cuneo-Pareto, S., Sangre de Cordón S.A. de C.V., Guadalajara, Mexico | |
| dc.description.abstract | Mesenchymal stem cells (MSCs) are of great interest for their potential use in cellular therapies. To define the population more precisely, diverse surface markers have been used. We propose here to use CD271 as the sole marker for MSCs in fresh bone marrow. We compared CD271+ populations to the presence or absence of five defined markers for MSCs: CD90+, CD105+, CD45-, CD34- and CD79. The correlations between markers were evaluated and analyzed with a Pearson's correlation test. We found that the average percentage of cells expressing the combination of markers CD90+, CD105+, CD45-, CD34- and CD79- was 0.54%, and that the average percentage average of CD271+ cells was 0.53%. The results were significant (p<0.05). The exclusive use of CD271 as a marker for MSCs from fresh samples of bone marrow appears to be highly selective. Using CD271 as the sole identification marker for MSCs could reduce costs and accelerate the process of identifying MSCs for the field of cellular therapy. © Polish Histochemical et Cytochemical Society. | |
